AI stock analysis · Drug Manufacturers - Specialty & Generic · Last analyzed Aug 18, 2026
AI Analyst Summary
Bausch Health is staging a significant earnings recovery — 70.4% YoY EPS growth and a forward P/E of just 1.6x suggest a deeply discounted turnaround play for investors willing to stomach substantial leverage and legal risk. The core specialty pharma portfolio and Bausch + Lomb equity stake provide real asset backing, and revenue growth of 12.7% confirms the underlying business is expanding. The critical risk is a crushing debt burden that constrains capital allocation and could undermine recovery if rates remain elevated or litigation outcomes worsen.
Fundamentals
Pe
N/A (loss-making / trailing P/E unavailable); Forward P/E: 1.6x · 3.0/5
Trailing P/E is unavailable due to prior losses, but a forward P/E of just 1.6x is remarkably low — even for a leveraged specialty pharma. This likely reflects deep market skepticism around debt load and litigation overhang rather than genuine undervaluation. Scored neutrally pending cleaner earnings trajectory.
Peg
PEG: 0.01 · 5.0/5
A PEG of 0.01 is extraordinarily low, driven by 70%+ YoY earnings growth against a near-zero price multiple. While technically exceptional, this figure is heavily distorted by the base effect of prior losses and elevated leverage — treated as a strong signal with caution.
Analyst Rating
Hold consensus (3.0) · 3.0/5
Consensus sits at exactly 3.0 with all 7 analysts rating Hold and zero Buy or Sell ratings. This reflects broad caution rather than conviction in either direction — analysts acknowledge improving fundamentals but remain wary of balance sheet risk and legal uncertainty. Capped at 3 per guidelines since the count is borderline.
Earnings Trend
EPS Growth YoY: +70.4% | Revenue Growth YoY: +12.7% · 4.0/5
Earnings growth of 70.4% YoY is well above the 25% threshold for a high score, and revenue growth of 12.7% provides solid underlying support. However, growth is recovering from a depressed base and is not yet confirmed as a multi-year acceleration, capping the score at 4 rather than 5.
Price Target Beat
EPS Beat Rate: 3 of 4 quarters · 2.0/5
With only 4 quarters of data available, 3 of 4 beats is encouraging but limited in statistical weight. Scored at 2 per guidelines for insufficient full 8-quarter history, treating the partial record conservatively. Execution is improving but not yet established.
Management
Mixed — improving execution, elevated debt concerns · 3.0/5
Management has delivered meaningful earnings recovery and revenue momentum, evidenced by 3 of 4 recent EPS beats and strong YoY growth. However, the legacy debt load, ongoing litigation from the Bausch + Lomb spin-off, and a uniformly cautious analyst community limit confidence in capital allocation quality. Scored neutrally.
● See the full picture
Get today's top-scored picks, ranked for you.
Compass screens thousands of stocks every morning and hands you a short list of high-conviction picks — scored, explained, and re-ranked to your risk profile.
Start free for 3 days →
No credit card. Then $9/month. Cancel anytime.
How Compass scores stocks
Compass pre-filters thousands of U.S. equities by fundamentals, then an AI analyst scores each finalist 1–5 across six measures — spanning valuation, growth, analyst sentiment, and management quality — into one composite score, refreshed every market morning. Browse all covered stocks →
Not financial advice.
Compass is an analytical tool, not a registered investment adviser or broker-dealer.
Scores and recommendations are generated by AI, may be inaccurate or out of date, and are
not investment, financial, legal, or tax advice. Investing involves risk, including loss of
principal. Do your own research and consult a licensed financial professional.
About Compass.